A Practical Approach for PD-L1 Evaluation in Gastroesophageal Cancer

Overview

Journal Pathologica

Specialty Pathology

Date 2022 Dec 20

PMID 36537078

Authors

Valentina Angerilli

Matteo Fassan

Paola Parente

Irene Gullo

Michela Campora

Chiara Rossi

Maria Luisa Sacramento

Gianmaria Pennelli

Alessandro Vanoli

Federica Grillo

Luca Mastracci

Affiliations

Soon will be listed here.

Abstract

PD-L1 is an established predictive immunohistochemical biomarker of response to immune checkpoint inhibitors. At present, PD-L1 is routinely assessed on biopsy samples of advanced gastroesophageal cancer patients before initiating first-line treatment. However, PD-L1 is still a suboptimal biomarker, due to changing cut-off values and scoring systems, interobserver and interlaboratory variability. This practical illustrated review discusses the range of staining patterns of PD-L1 and the potential pitfalls and challenges that can be encountered when evaluating PD-L1, focusing on gastric and gastroesophageal adenocarcinoma (G/GEA) and esophageal squamous cell carcinoma (ESCC).

Citing Articles

Spatial and Temporal Tumor Heterogeneity in Gastric Cancer: Discordance of Predictive Biomarkers.

Lee H J Gastric Cancer. 2025; 25(1):192-209.

PMID: 39822175 PMC: 11739643. DOI: 10.5230/jgc.2025.25.e3.

Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer.

Kim T, Kwak Y, Nam S, Han D, Oh D, Im S ESMO Open. 2024; 9(12):104000.

PMID: 39615405 PMC: 11648117. DOI: 10.1016/j.esmoop.2024.104000.

References

Darvin P, Toor S, Sasidharan Nair V, Elkord E . Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018; 50(12):1-11. PMC: 6292890. DOI: 10.1038/s12276-018-0191-1. View

Chang S, Park H, Choi Y, Jang S . Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists. J Pathol Transl Med. 2019; 53(6):347-353. PMC: 6877442. DOI: 10.4132/jptm.2019.09.29. View

Butter R, t Hart N, Hooijer G, Monkhorst K, Speel E, Theunissen P . Multicentre study on the consistency of PD-L1 immunohistochemistry as predictive test for immunotherapy in non-small cell lung cancer. J Clin Pathol. 2019; 73(7):423-430. DOI: 10.1136/jclinpath-2019-205993. View

Gou Q, Dong C, Xu H, Khan B, Jin J, Liu Q . PD-L1 degradation pathway and immunotherapy for cancer. Cell Death Dis. 2020; 11(11):955. PMC: 7648632. DOI: 10.1038/s41419-020-03140-2. View

Lawlor R, Mafficini A, Sciammarella C, Cantu C, Rusev B, Piredda M . Genomic characterization of hepatoid tumors: context matters. Hum Pathol. 2021; 118:30-41. DOI: 10.1016/j.humpath.2021.09.006. View

Ajani J, DAmico T, Bentrem D, Chao J, Cooke D, Corvera C . Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022; 20(2):167-192. DOI: 10.6004/jnccn.2022.0008. View

Ye M, Huang D, Zhang Q, Weng W, Tan C, Qin G . Heterogeneous programmed death-ligand 1 expression in gastric cancer: comparison of tissue microarrays and whole sections. Cancer Cell Int. 2020; 20:186. PMC: 7247123. DOI: 10.1186/s12935-020-01273-0. View

Xu H, Lin G, Huang C, Zhu W, Miao Q, Fan X . Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer. Sci Rep. 2017; 7(1):16956. PMC: 5717240. DOI: 10.1038/s41598-017-17034-5. View

Morihiro T, Kuroda S, Kanaya N, Kakiuchi Y, Kubota T, Aoyama K . PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer. Sci Rep. 2019; 9(1):4633. PMC: 6420501. DOI: 10.1038/s41598-019-41177-2. View

10.

Gullo I, Oliveira P, Athelogou M, Goncalves G, Pinto M, Carvalho J . New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression. Gastric Cancer. 2018; 22(1):77-90. DOI: 10.1007/s10120-018-0836-8. View

11.

Mastracci L, Grillo F, Parente P, Gullo I, Campora M, Angerilli V . PD-L1 evaluation in the gastrointestinal tract: from biological rationale to its clinical application. Pathologica. 2022; 114(5):352-364. PMC: 9614301. DOI: 10.32074/1591-951X-803. View

12.

Grillo F, Bruzzone M, Pigozzi S, Prosapio S, Migliora P, Fiocca R . Immunohistochemistry on old archival paraffin blocks: is there an expiry date?. J Clin Pathol. 2017; 70(11):988-993. DOI: 10.1136/jclinpath-2017-204387. View

13.

Businello G, Angerilli V, Lonardi S, Bergamo F, Valmasoni M, Farinati F . Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter. Updates Surg. 2022; 75(2):291-303. PMC: 9852175. DOI: 10.1007/s13304-022-01330-5. View

14.

Buchwalow I, Samoilova V, Boecker W, Tiemann M . Non-specific binding of antibodies in immunohistochemistry: fallacies and facts. Sci Rep. 2012; 1:28. PMC: 3216515. DOI: 10.1038/srep00028. View

15.

Booth M, Smyth E . Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy. BioDrugs. 2022; 36(4):473-485. DOI: 10.1007/s40259-022-00527-9. View

16.

Gullo I, Grillo F, Mastracci L, Vanoli A, Carneiro F, Saragoni L . Precancerous lesions of the stomach, gastric cancer and hereditary gastric cancer syndromes. Pathologica. 2020; 112(3):166-185. PMC: 7931572. DOI: 10.32074/1591-951X-166. View

17.

Nakamura Y, Kawazoe A, Lordick F, Janjigian Y, Shitara K . Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nat Rev Clin Oncol. 2021; 18(8):473-487. DOI: 10.1038/s41571-021-00492-2. View

18.

Yeong J, Lum H, Teo C, Tan B, Chan Y, Tay R . Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Gastric Cancer. 2022; 25(4):741-750. PMC: 9226082. DOI: 10.1007/s10120-022-01301-0. View

19.

Fassan M, Brignola S, Pennelli G, Alberti G, Angerilli V, Bressan A . PD-L1 expression in gastroesophageal dysplastic lesions. Virchows Arch. 2019; 477(1):151-156. DOI: 10.1007/s00428-019-02693-8. View

20.

Ahn S, Kim K . PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy. Mod Pathol. 2021; 34(9):1719-1727. DOI: 10.1038/s41379-021-00823-9. View